

Special Issue

Advanced Prostate Cancer: From Bench to Bedside

Message from the Guest Editor

Prostate cancer is generally viewed as a slow-growing unaggressive cancer, yet it is one of the most commonly diagnosed cancers and a leading cause of morbidity and mortality in men around the world. Over the last few years, the management of advanced prostate cancer has evolved tremendously, leading to new therapeutic options that have helped to improve survival and quality of life. All of this success is due to intensive research that has gone from preclinical models and through the phases of clinical research to eventually lead to what we now have to offer. This Special Edition looks to cover what is presently available and how best to use these therapeutic options in advanced/metastatic castration-sensitive as well as castration-resistant prostate cancer. This issue will address ongoing basic and clinical research that may lead to new therapies but also how to better use the options we have at our disposal, whether it be in terms of timing, combination, and sequencing. This issue will also look to include the exponential growth of molecular imaging and radioligand therapy over the past few years.

Guest Editor

Prof. Dr. Fred Saad

Department of Surgery, University of Montréal, P.O. Box 6128, Montréal, QC, Canada

Deadline for manuscript submissions

closed (31 December 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/66052

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)